Quotidian Technical Highlights on Selected Drug Makers Stocks -- Depomed, DURECT, Endo, and Ionis Pharma

Monday, March 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 26, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on DEPO, DRRX, ENDP, and IONS which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has selected the following Drug Manufacturers stocks for review: Depomed Inc. (NASDAQ:
DEPO), DURECT Corp. (NASDAQ: DRRX), Endo International PLC (NASDAQ: ENDP), and Ionis Pharmaceuticals Inc. (NASDAQ: IONS). Companies in the Pharmaceutical Manufacturing industry manufacture and process pharmaceutical products. They focus on the most profitable markets, where demand for treatment is high. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Depomed

Newark, California headquartered Depomed Inc.'s shares recorded a trading volume of 592,540 shares last Friday. The stock finished the trading session 4.24% lower at $6.32. The Company's shares are trading below their 50-day moving average by 12.85%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 34.25.  

On March 19th, 2018, Depomed announced that the Company has signed a lease for its new corporate headquarters at 100 South Saunders Road in Lake Forest, Illinois, a northern Chicago suburb. The Company anticipates the new headquarters, located in the Landmark Conway Farms complex, to be operational in the third quarter of the calendar year. Get the full research report on DEPO for free by clicking below at:

www.wallstequities.com/registration/?symbol=DEPO

DURECT

On Friday, Cupertino, California headquartered DURECT Corp.'s stock ended the session 0.45% higher at $2.24. A total volume of 1.95 million shares was traded, which was above their three months average volume of 876,330 shares. The Company's shares have surged 100.00% in the last month, 124.56% over the previous three months, and 134.70% over the past year. The stock is trading 62.86% above its 50-day moving average and 59.98% above its 200-day moving average. Moreover, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 91.39.  

On March 06th, 2018, research firm H.C. Wainwright upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $3.50 per share.

On March 20th, 2018, DURECT announced that its licensee, Pain Therapeutics, reported on March 19th, 2018, that the US FDA will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended release oxycodone CII). The tentative date for the Advisory Committee Meeting is June 26th, 2018. The Prescription Drug User Fee Act target date for the REMOXY ER NDA is August 07th, 2018. The free technical report on DRRX can be accessed at:

www.wallstequities.com/registration/?symbol=DRRX

Endo International

Dublin, Ireland headquartered Endo International PLC's stock ended the day 3.14% lower at $5.86 with a total trading volume of 3.76 million shares. The stock is trading 15.31% below their 50-day moving average. Shares of the Company, which manufactures and sells generic and branded pharmaceuticals in the US, Canada, and internationally, have an RSI of 30.53.  

On February 28th, 2018, research firm Gabelli & Co downgraded the Company's stock rating from 'Buy' to 'Hold'.

On March 01st, 2018, Endo International announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict®, the first and only vasopressin injection, USP, product approved by the US FDA. Sign up for free on Wall St. Equities and claim the latest report on ENDP at:

www.wallstequities.com/registration/?symbol=ENDP

Ionis Pharmaceuticals

Shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. recorded a trading volume of 1.01 million shares, which was above their three months average volume of 978,630 shares. The stock ended Friday's session 5.99% lower at $47.74. The Company's shares have gained 25.86% over the past year. The stock is trading below its 50-day moving average by 6.84%. Furthermore, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 37.12.  

On March 15th, 2018, Ionis Pharma (IONS) and Akcea Therapeutics, Inc. (AKCA) announced an exclusive, worldwide license by the former to the latter for inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth up to approximately $1.7 billion to IONS plus profit sharing payments. The newly combined AKCA's team is preparing to launch inotersen in the US and EU following planned approvals in mid-2018 to treat people with hereditary transthyretin amyloidosis, or hATTR, a systemic, progressive, and fatal disease. See the free research coverage on IONS at:

www.wallstequities.com/registration/?symbol=IONS

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-drug-makers-stocks----depomed-durect-endo-and-ionis-pharma-300619230.html

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store